SK Biopharmaceuticals Ratios and Metrics

Market cap in millions KRW. Fiscal year is January - December.

Millions KRW. Fiscal year is Jan - Dec.

Fiscal Year	Current	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Mar '26 Mar 5, 2026	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020
Market Capitalization	8,058,433	8,700,602	7,862,650	5,646,385	7,612,048	13,234,939
Market Cap Growth	-19.55%	10.66%	39.25%	-25.82%	-42.48%	-
Enterprise Value	7,868,299	8,637,734	7,807,605	5,442,304	7,267,516	12,840,764
Last Close Price	102900.00	111100.00	100400.00	72100.00	97200.00	169000.00
PE Ratio	25.15	36.14	-	-	117.39	-
Forward PE	30.48	73.81	-	-	-	-
PS Ratio	11.93	15.89	22.16	22.94	18.18	509.06
PB Ratio	11.69	15.16	24.50	17.84	17.14	34.92
P/TBV Ratio	12.12	16.24	29.59	18.86	17.90	36.83
P/FCF Ratio	56.33	93.05	-	-	-	-
P/OCF Ratio	55.13	91.68	-	-	-	-
EV/Sales Ratio	11.65	15.77	22.00	22.11	17.36	493.89
EV/EBITDA Ratio	44.83	75.93	-	-	68.18	-
EV/EBIT Ratio	49.78	89.66	-	-	76.53	-
EV/FCF Ratio	55.00	92.38	-	-	-	-
Debt / Equity Ratio	0.07	0.32	0.56	0.49	0.04	0.05
Debt / EBITDA Ratio	0.23	1.62	-	-	0.15	-
Debt / FCF Ratio	0.35	1.97	-	-	-	-
Net Debt / Equity Ratio	-0.30	-0.24	-0.20	-0.47	-0.72	-0.97
Net Debt / EBITDA Ratio	-0.96	-1.23	2.84	1.27	-2.99	1.62
Net Debt / FCF Ratio	-1.45	-1.50	0.65	0.91	3.28	1.67
Asset Turnover	0.75	0.62	0.51	0.38	0.73	0.08
Inventory Turnover	0.31	0.40	0.35	0.53	0.60	0.13
Quick Ratio	1.84	1.26	1.47	2.28	2.64	5.67
Current Ratio	2.43	1.64	2.02	2.99	3.18	6.16
Return on Equity (ROE)	58.15%	50.72%	-11.10%	-36.66%	15.75%	-135.18%
Return on Assets (ROA)	13.73%	6.84%	-3.38%	-12.53%	10.38%	-46.83%
Return on Invested Capital (ROIC)	41.79%	27.85%	-17.66%	-89.60%	127.86%	-2063.82%
Return on Capital Employed (ROCE)	25.90%	15.00%	-7.80%	-26.20%	19.20%	-55.70%
Earnings Yield	3.98%	2.77%	-0.42%	-2.47%	0.85%	-1.87%
FCF Yield	1.78%	1.07%	-1.23%	-2.92%	-1.28%	-1.68%
Buyback Yield / Dilution	-	-	-	-	-9.12%	-10.41%

Updated Sep 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.